Jefferies Financial Group Reaffirms “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Financial Group in a report issued on Tuesday, Digital Look reports. They presently have a GBX 2,500 price objective on the stock. Jefferies Financial Group’s price objective would suggest a potential upside of 33.80% from the stock’s current price.

Several other research analysts have also weighed in on GSK. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research report on Tuesday, September 29th. Berenberg Bank boosted their price target on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a research note on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Trading Up 0.7%

LON:GSK traded up GBX 13.50 during trading hours on Tuesday, reaching GBX 1,868.50. 5,106,011 shares of the company were exchanged, compared to its average volume of 12,483,875. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The firm has a market cap of £74.87 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 1.24 and a beta of 0.29. GSK has a 52-week low of GBX 1,592 and a 52-week high of GBX 2,282. The stock has a 50 day simple moving average of GBX 1,845.12 and a 200 day simple moving average of GBX 1,922.33.

GSK (LON:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, analysts predict that GSK will post 175.98 EPS for the current year.

Insider Activity

In related news, insider Anne Beal bought 637 shares of the stock in a transaction dated Friday, September 18th. The stock was acquired at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction dated Friday, September 18th. The stock was bought at an average price of GBX 1,881 per share, with a total value of £28,215. Insiders bought 2,151 shares of company stock valued at $6,021,921 in the last ninety days. Company insiders own 0.20% of the company’s stock.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK finalized an exclusive global license agreement with HUTCHMED for HMPL-A830, an experimental targeted therapy designed for KRAS-altered colorectal, pancreatic and lung cancers. GSK will lead development after the global Phase I program and will hold commercialization rights outside mainland China, Hong Kong, Macau and Taiwan, expanding its precision-oncology pipeline. HUTCHMED Announces Closing of Exclusive Global License Agreement with GSK for HMPL-A830
• Positive Sentiment: The FDA approved Jemperli for certain patients with advanced rectal cancer. The approval broadens the drug’s addressable market and could support future oncology revenue, although commercial uptake and the eligible patient population remain important variables. GSK’s Jemperli scores FDA approval in rectal cancer
• Positive Sentiment: GSK reported a 61% response rate in an early Phase 1b trial of risvutatug rezetecan in lung cancer, adding evidence that the candidate could become a meaningful future oncology product. Because the data are early-stage, larger trials will be needed to confirm efficacy and safety. GSK Says Drug Candidate Risvutatug Rezetecan Shows 61% Response Rate
• Positive Sentiment: Jefferies reaffirmed its Buy rating and set a GBX 2,500 price target, signaling continued analyst confidence in GSK’s valuation and pipeline. Jefferies rating update
• Neutral Sentiment: GSK plans to invest $800 million in Philadelphia-area life-sciences and manufacturing facilities. The spending may improve long-term capacity and employment but represents near-term capital investment. GSK to invest $800M in Metro Philadelphia facilities

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.